I think it's just patience at this point. This was always a high risk, high reward play, and the game is far from over. The real wildcard, from an investor's point of view, is the new CEO. This is a younger, dynamic, media-friendly guy. It also doesn't hurt that he is Hispanic, bilingual and willing to pursue foreign markets. I love the work that Jim Musick has done, but he is clearly better suited to his new role as CSO. With a more aggressive, media-friendly person at the helm, a lot more people will learn about the company, and that will fuel investment interest after they re-file. The future is unpredictable, but I do expect them to be listed again before summer, and, after a shaky start (final buying opportunity?), I expect the stock to move past a dollar and stay there for a while. What happens after that will depend on performance and the M&A environment that I expect to develop for legitimate stem cell companies over the next few years.
